To validate the role of pro-tumor neutrophils/G-MDSCs in our model, we next measured the effect of treating lesion-bearing animals with SX-682, a small molecule inhibitor of CXCR1/2 reported to target G-MDSCs (currently in phase I trials for melanoma, NCT03161431). The gene discussed is CXCR1; the disease is neoplasm.